Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia

Pathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger than 50 years. The current treatment of subfoveal myopic choroidal neovascularization (mCNV) is verteporfin photodynamic therapy, but its long-...

Celý popis

Podrobná bibliografie

Vydáno v:	Retina (Philadelphia, Pa.) Ročník 29; číslo 8; s. 1062
Hlavní autor:	Cohen, Salomon Y
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.09.2009
Témata:	Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Humans Myopia, Degenerative - complications Myopia, Degenerative - drug therapy Ranibizumab Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects
ISSN:	1539-2864, 1539-2864
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!